Special Issue

COVID-19 and Its Co-infection

Message from the Guest Editors

Because the clinical manifestation of SARS-CoV-2 infection can range from asymptomatic, mild disease to severe or critical COVID-19, we needed different treatment strategies according to the disease severity of COVID-19. For patients with mild disease, appropriate antiviral agents or neutralized monoclonal antibody may help to enhance clinical improvement and prevent disease progression. For patients with severe-to-critical COVID-19, anti-inflammatory agents are key to management for these stages with exaggerated inflammation. In addition, co-infection with bacteria. viruses, and fundi can develop in patients with COVID-19, especially those with severe diseases. Therefore, determining how to identify patients with co-infection and appropriately use antimicrobial agents should also be a topic of concern. This Special Issue of Life (MDPI) will focus on the management of COVID-19 in three ways, including anti-SARS-CoV-2 agents, antiinflammatory agents, and antimicrobial agents for COVID-19 co-infections. Studies covering these three issues will be welcome.

Guest Editors

Dr. Chih-Cheng Lai

Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 710, Taiwan

Dr. Yen-Hung Liu

Department of Internal Medicine, Cardinal Tien Hospital, School of Medicine, Fu Jen Catholic University, New Taipei City 242062, Taiwan

Deadline for manuscript submissions

closed (25 September 2022)



Life

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



mdpi.com/si/116634

Life
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

mdpi.com/journal/ life





Life

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)

